Kymera Therapeutics (KYMR) Projected to Release Earnings on Wednesday

Kymera Therapeutics (NASDAQ:KYMR) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Kymera Therapeutics to announce earnings of ($0.7126) per share and revenue of $32.7760 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.82) EPS. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kymera Therapeutics Stock Down 2.1%

Shares of KYMR traded down $2.17 during trading hours on Monday, reaching $101.23. 23,786 shares of the company traded hands, compared to its average volume of 738,508. Kymera Therapeutics has a 12 month low of $36.65 and a 12 month high of $130.05. The company’s fifty day moving average price is $98.92 and its two-hundred day moving average price is $87.77. The company has a market capitalization of $8.33 billion, a price-to-earnings ratio of -28.43 and a beta of 1.95.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Mizuho upped their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Bank of America upped their price target on Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Truist Financial boosted their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a report on Monday, June 29th. B. Riley Financial lifted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Kymera Therapeutics in a research report on Thursday. They set a “hold” rating and a $120.00 price objective for the company. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.48.

Insider Activity

In related news, CFO Bruce N. Jacobs sold 77,109 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the transaction, the chief financial officer directly owned 244,883 shares in the company, valued at $28,151,749.68. The trade was a 23.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce Booth sold 467,878 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the transaction, the director directly owned 472,267 shares in the company, valued at $52,086,327.43. This trade represents a 49.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,607,813 shares of company stock valued at $387,818,004 over the last ninety days. 15.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. lifted its stake in Kymera Therapeutics by 3.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock valued at $49,001,000 after acquiring an additional 18,524 shares during the period. Invesco Ltd. lifted its position in Kymera Therapeutics by 46.3% during the fourth quarter. Invesco Ltd. now owns 116,747 shares of the company’s stock valued at $9,084,000 after purchasing an additional 36,940 shares during the period. Vident Advisory LLC lifted its position in Kymera Therapeutics by 6.5% during the fourth quarter. Vident Advisory LLC now owns 7,581 shares of the company’s stock valued at $590,000 after purchasing an additional 465 shares during the period. Mackenzie Financial Corp purchased a new stake in Kymera Therapeutics in the fourth quarter worth approximately $270,000. Finally, XTX Topco Ltd bought a new stake in Kymera Therapeutics in the 4th quarter worth approximately $1,879,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.